Silver Book

Silver Book Fact

Potential savings from shingles vaccine

Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles, post-herpetic neuralgia, and other complications.

Pellesier J, Brisson M, Levin M. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier J, Brisson M, Levin M
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
  • Eradication of infectious diseases from vaccination
    Spanning more than 200 years of research and development, 10 infectious diseases have been at least 90 percent eradicated in the United States thanks to vaccines.  
  • Shingles vaccine reduces incidence by >50%
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.  
  • Eradication of smallpox has saved 40 million lives worldwide
    Since global vaccination efforts wiped out smallpox disease in 1979, infections in 350 million people have been prevented and 40 million lives have been saved.